The DLEC1 Polyclonal Antibody (PACO08851) is a key tool for researchers studying DLEC1, a tumor suppressor gene associated with various types of cancer. This antibody, generated in rabbits, exhibits high specificity and sensitivity in detecting DLEC1 protein in human samples, making it suitable for use in Western blot applications. By binding to DLEC1, this antibody allows for precise identification and analysis of DLEC1 expression in different cell types, making it an essential component for cancer research and molecular biology studies.DLEC1, also known as deleted in lung and esophageal cancer 1, is a critical factor in regulating cell growth, proliferation, and apoptosis, making it a focal point for understanding cancer development and progression.
By investigating the role of DLEC1 in various cancers, researchers can uncover potential therapeutic targets and diagnostic markers for precision medicine approaches. The DLEC1 Polyclonal Antibody provides a valuable tool for deciphering the mechanisms underlying DLEC1 function and its implications in oncology, offering new avenues for developing novel cancer treatments.
deleted in lung and esophageal cancer 1;DLEC1;DLC1;F56 ;
UniProt Protein Function:
DLEC1: May act as a tumor suppressor by inhibiting cell proliferation. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of different cancers, including esophageal (ESCR), renal and lung cancers (LNCR). Defects in DLEC1 are a cause of lung cancer (LNCR). A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of lung cancer. Defects in DLEC1 are a cause of esophageal cancer (ESCR). A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. DLEC1 silencing due to promoter methylation and aberrant transcription are implicated in the development of esophageal cancer. 3 isoforms of the human protein are produced by alternative splicing.Protein type: Tumor suppressorChromosomal Location of Human Ortholog: 3p21.3Cellular Component: cytoplasmDisease: Esophageal Cancer; Lung Cancer
UniProt Protein Details:
NCBI Summary:
The cytogenetic location of this gene is 3p21.3, and it is located in a region that is commonly deleted in a variety of malignancies. Down-regulation of this gene has been observed in several human cancers including lung, esophageal, renal tumors, and head and neck squamous cell carcinoma. In some cases, reduced expression of this gene in tumor cells is a result of aberrant promoter methylation. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins.[provided by RefSeq, Mar 2016]
